Hugh Sampson - DBV Technologies Chief Scientific Officer
Executive
Mr. Hugh A. Sampson, M.D., is an Chief Scientific Officer of the Company. effective on November 1, 2015. Hugh A. Sampson, M.D., is a professor of Pediatrics at the Icahn School of Medicine at Mount Sinai School, N.Y., USA. He is Director of the Jaffe Food Allergy Institute and Dean of Translational Biomedical Science at The Mount Sinai Medical Center. He received his M.D. from the State University of New York at Buffalo School of Medicine. Dr. Sampson research interests have focused on food allergic disorders, including work on the immunopathogenic role of food hypersensitivity in atopic dermatitis, the pathogenesis of foodinduced anaphylaxis, the characterization of foodinduced gastrointestinal hypersensitivities, the characterization of food allergens, and novel immunotherapeutic strategies for treating food allergies. His research was funded by a number of grants from the National Institutes of Health and private foundations. He is the Principal Investigator of the NIHsponsored Consortium of Food Allergy Research . He is also former President of the American Academy of Allergy Asthma and Immunology . since 2015.
| Tenure | 9 years |
| Phone | 33 1 55 42 78 78 |
| Web | https://www.dbv-technologies.com |
DBV Technologies Management Efficiency
The company has return on total asset (ROA) of (31.96) % which means that it has lost $31.96 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (67.72) %, meaning that it generated substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 4.63 M in total debt with debt to equity ratio (D/E) of 0.06, which may suggest the company is not taking enough advantage from borrowing. DBV Technologies has a current ratio of 3.4, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist DBV Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, DBV Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DBV Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for DBV to invest in growth at high rates of return. When we think about DBV Technologies' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Zhiyun Tan | Integrated Media Technology | N/A | |
| Motti Gil | NeogamesSA | 51 | |
| Mohd Rosmey | Integrated Media Technology | N/A | |
| James Claffey | Sphere Entertainment Co | N/A | |
| MBA CPFA | Bausch Lomb Corp | 64 | |
| Jonathon Kellerman | Bausch Lomb Corp | N/A | |
| George Yatzis | Integrated Media Technology | N/A | |
| Gabby Naftali | NeogamesSA | N/A | |
| Ari CFA | Sphere Entertainment Co | N/A | |
| Yehia MD | Bausch Lomb Corp | 57 | |
| A Bailey | Bausch Lomb Corp | 61 | |
| Asli Gevgilili | Bausch Lomb Corp | N/A | |
| Thomas Hickey | Iridium Communications | 58 | |
| Howard Cyr | Teleflex Incorporated | N/A | |
| Laura Franco | Sphere Entertainment Co | 61 | |
| Richard Constable | Sphere Entertainment Co | N/A | |
| Joel Fisher | Sphere Entertainment Co | N/A | |
| Manisha Narasimhan | Bausch Lomb Corp | 47 | |
| Christopher Shaban | NeogamesSA | N/A | |
| Ray Casazza | Sphere Entertainment Co | N/A | |
| T Crawford | Bausch Lomb Corp | N/A | |
Management Performance
| Return On Equity | -67.72 | |||
| Return On Asset | -31.96 |
DBV Technologies Leadership Team
Elected by the shareholders, the DBV Technologies' board of directors comprises two types of representatives: DBV Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DBV. The board's role is to monitor DBV Technologies' management team and ensure that shareholders' interests are well served. DBV Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DBV Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pascale Ehouarn, Industrial Development and Production Director | ||
| Claude Thebault, Medical Director | ||
| Wence Agbotounou, Chief Clinical Trial Officer | ||
| Laurent Martin, Director of Regulatory Affairs | ||
| Viviane Monges, Director | ||
| Didier Hoch, Director | ||
| Hugh Sampson, Chief Scientific Officer | ||
| Charles Ruban, Chief Development Officer | ||
| Nathalie Donne, Director of Bus. Devel. and Corporate Communication | ||
| Lucie Mondoulet, Director of Research Department | ||
| Chahra Louafi, Director - Representative of CDC Entreprises (Innobio) | ||
| Peter Hutt, Independent Director | ||
| Rafaele Tordjman, Director - Representative of Sofinnova Partners | ||
| Bertrand Dupont, Co-Founder and Sr. Executive VP of Technology | ||
| Veronique Foutel, Director of Strategic Marketing | ||
| FAAAAI MD, Chief Scientific Officer, Advisor and Member of The Scientific Advisory Board | ||
| Daniel Tasse, CEO, Director | ||
| Rafale Tordjman, Director - Representative of Sofinnova Partners | ||
| Joan Schmidt, Executive Vice President General Counsel | ||
| George Horner, Director | ||
| Torbjorn Bjerke, Independent Director | ||
| Pharis Mohideen, Chief Medical Officer | ||
| PierreHenri Benhamou, Chairman of the Board, CEO | ||
| Torbjrn Bjerke, Independent Director | ||
| Mailys Ferrere, Director | ||
| Michel Rosen, Director | ||
| David Schilansky, COO |
DBV Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is DBV Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -67.72 | |||
| Return On Asset | -31.96 | |||
| Operating Margin | (952.83) % | |||
| Current Valuation | 84.39 M | |||
| Shares Outstanding | 29.98 M | |||
| Shares Owned By Insiders | 6.53 % | |||
| Shares Owned By Institutions | 37.62 % | |||
| Price To Earning | (12.55) X | |||
| Price To Book | 1.88 X | |||
| Price To Sales | 11.03 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards DBV Technologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, DBV Technologies' short interest history, or implied volatility extrapolated from DBV Technologies options trading.
Pair Trading with DBV Technologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DBV Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DBV Technologies will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Flowserve could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Flowserve when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Flowserve - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Flowserve to buy it.
The correlation of Flowserve is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Flowserve moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Flowserve moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Flowserve can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in DBV OTC Stock
If you are still planning to invest in DBV Technologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DBV Technologies' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |